Exhibit E

Financial Plan and Forecast

Financial Plan
Key Assumptions

The financial projections herein are believed to be reasonable and attainable within the projected 3-year period but are for illustrative purposes only. We are projecting sales growth by an average of 500 new remote patient monitoring accounts each month from various healthcare networks and medical practices throughout the United States. The 500 accounts are an average figure per month over the 36-month period, but we anticipate unpredictable swings in actual account volume on a month-to-month basis.
The projections assume a churn rate of 1% per month of total accounts, or an attrition rate of 12% per year. CLOVIS AI has implemented procedures to reduce churn, especially from non-compliance to vitals testing as the system sends missed measurement alerts for immediate support team or chronic care management follow-up. Patients who have difficulty adhering to measurement protocols can be issued wrist watches that monitor and report their vital signs automatically on a continual basis.
Direct Costs include payment for the suite of Bluetooth monitoring equipment and the Clovis cellular router for each new account, plus the recurring monthly nurse consulting fees (Angel Support) and data transmission costs for all active accounts.
Long term assets include the capitalized value of $1,350,000 from HME Technology’s contribution of research and development of the RPM router and system. The contribution by the Managing Director of an active contract in Georgia is valued at $900,000 in future receivables and has been amortized over three years in the Financing section along with net proceeds from the maximum Offering of $890,000.
Early cash flow will be reinvested into operations, marketing, and growth. Not shown in the projections are the potential for Partnership distributions in years two and three on a pro rata basis to Unit Holders. There is no federal Income tax liability shown since the Partnership is a flow-through entity for tax purposes and gains and losses will be passed through to Units Holders via IRS Schedule K-1.

Use of funds
Funds raised in this Offering will primarily be used to purchase routers and monitoring equipment inventory to fulfil orders for our Remote Patient Monitoring (RPM) Program.
Initial overhead is minimal as operations are currently overseen from a residence and no salaries are being paid or have accrued. Margins are sufficient to operate the Partnership
at reduced levels with even the minimum Offering amount being raised.
The projections herein assume the maximum Offering amount of $1 million will be raised, thus dramatically increasing revenue growth and operational flexibility. The net proceeds
from a maximum raise will be approximately $890,000 and will be purposed as follows:

Sources of Funds
Management of the Partnership has contributed intellectual property and active receivable contracts worth approximately $2.3 million and have personally funded initial
start-up expenses to date without taking any compensation and will continue to do so until the minimum Offering amount is raised and escrow on the funding account is lifted.
This Offering will be presented to select medical professionals and a limited number of referrals for the opportunity to participate in the Partnership. Management fully expects
the Offering to be fully subscribed to and funded prior to the end of the 180-day stated offering period.
Please refer to the accompanying Confidential Private Offering Memorandum for complete details and Offering documents.

Clovis AI LLC
FY2023-FY2025 Forecast

(July 1 through June 30)

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents